Scientific Sessions 2024  /  Featured Science: Novel Approaches to Managing Lipid Risk  /  Discussant: YELLOW III
Logo

American Heart Association

  210
  0

Final ID:

Discussant: YELLOW III

  • Mora, Samia  ( BRIGHAM AND WOMENS HOSPITAL , Boston , Massachusetts , United States )
  • Kramer, Christopher  ( Univ. of Virginia Health System , Charlottesville , Virginia , United States )
    • Author Disclosures:
    Samia Mora: DO have relevant financial relationships ; Royalties/Patent Beneficiary:co-inventor on patent application on glycosylation and cardiovascular disease issued to Genos and Brigham and Women's Hospital:Active (exists now) | Christopher Kramer: DO have relevant financial relationships ; Research Funding (PI or named investigator):BMS:Active (exists now) ; Research Funding (PI or named investigator):Cytokinetics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

Discussant: LIBerate-OLE, LIBerate-HeFH_OLE

O'donoghue Michelle

More abstracts from these authors:
What a New CV Board Might Mean for Me?

Kramer Christopher, Fry Edward

Effect of Tirzepatide on Cardiac Structure and Function in Obese HFpEF: the SUMMIT CMR Substudy

Kramer Christopher

You have to be authorized to contact abstract author. Please, Login
Not Available